ClinicalTrials.gg
CompletedNCT03996369ELEVATE UC 12Updated Dec 21, 2022Results posted

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

A Phase 3 interventional study of Etrasimod and Placebo in Ulcerative Colitis, sponsored by Arena Pharmaceuticals. Completed at 407 sites in 41 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-12-21.

Sponsored by Arena Pharmaceuticals (part of Pfizer) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
354
Allocation
Randomized
Ages
16 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing etrasimod in Colitis, Ulcerative — 3 open to participants now, 5 under way, 2 of them phase 3. etrasimod · Colitis, Ulcerative.

Enrollment
3rd of 12
354 · median 195
Started
2020
with 1 other
Phase 3
5 of 12
none open now
Registered
5th of 12
by date
Lead sponsor
4 of 12
Arena Pharmaceuticals

Among the 12 studies testing etrasimod in Colitis, Ulcerative, this one is the 3rd largest by enrollment, is one of 2 that started in 2020, is one of 5 in phase 3, and was the 5th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 12 studies testing etrasimod in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About etrasimod

etrasimod: first FDA approval 2023 (VELSIPITY), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 16 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing etrasimod in Colitis, Ulcerative, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy of etrasimod on clinical remission in participants with moderately to severely active ulcerative colitis (UC).

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

Keywords

  • Ulcerative Colitis
  • Etrasimod
  • APD334
04

Who can participate

Ages eligible
16 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with ulcerative colitis (UC) ≥ 3 months prior to screening
  • Active UC confirmed by endoscopy

Exclusion criteria

Exclusion Criteria:

  • Severe extensive colitis
  • Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history of a fistula consistent with CD
  • Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
354 participants (actual)

Study arms

  • Experimental
    Etrasimod 2 mg

    Drug: Etrasimod

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Etrasimod 2 mg tablet by mouth, once daily up to 12-Week Induction Treatment Period

    Also known as: APD334

  • DrugPlacebo

    Etrasimod matching placebo tablet by mouth, once daily up to 12-Week Induction Treatment Period

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Clinical Remission

    Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily electronic (e)-diary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF sub-score = 0 (or = 1 with a greater than or equal to \[\>=\] 1-point decrease from Baseline), RB sub-score = 0, and ES less than or equal to (\<=) 1 (excluding friability). Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Achieving Endoscopic Improvement

    Endoscopic improvement was defined as an ES \<= 1 (excluding friability). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease); higher score indicated more severe disease.

    Time frame: Week 12

  2. Percentage of Participants Achieving Symptomatic Remission

    Symptomatic remission was defined as an SF sub-score = 0 (or = 1 with a \>= 1 point decrease from Baseline) and RB sub-score = 0. The SF sub-score ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicated more severe disease.

    Time frame: Week 12

  3. Percentage of Participants With Mucosal Healing

    Mucosal healing was defined as an ES \<= 1 (excluding friability) with histologic remission measured by a Geboes Index score less than \[\<\] 2.0). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system, was a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicated more severe disease.

    Time frame: Week 12

  4. Percentage of Participants Achieving Clinical Response

    Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a \>= 2-point and \>= 30 percent (%) decrease from Baseline MMS, and a \>= 1-point decrease from Baseline in RB sub-score or an absolute RB sub-score \<= 1. Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

    Time frame: Week 12

  5. Percentage of Participants Achieving Endoscopic Normalization

    Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease); higher score indicated more severe disease.

    Time frame: Week 12

  6. Percentage of Participants Achieving Symptomatic Remission at Weeks 2, 4 and 8

    Symptomatic remission was defined as an SF sub-score = 0 (or = 1 with a \>= 1 point decrease from Baseline) and RB sub-score = 0. The SF sub-score ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicated more severe disease.

    Time frame: Weeks 2, 4 and 8

  7. Percentage of Participants Achieving Complete Symptomatic Remission

    Complete symptomatic remission was defined as an SF sub-score = 0 and RB sub-score = 0. The SF sub-score ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicated more severe disease.

    Time frame: Weeks 2, 4, 8 and 12

  8. Percentage of Participants Achieving Non-invasive Clinical Response

    Non-invasive clinical response was defined as a \>= 30% decrease from Baseline in composite RB and SF sub-scores, and a \>= 1 point decrease from Baseline in RB sub-score or RB sub-score \<= 1. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.

    Time frame: Weeks 2, 4, 8 and 12

  9. Percentage of Participants Achieving Symptomatic Response

    Symptomatic response was defined as a \>= 30% decrease from Baseline in composite RB and SF score. The SF sub-score ranged from 0 to 3 (where 0= normal number of stools and 3= at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0= no blood and 3= blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.

    Time frame: Weeks 2, 4, 8 and 12

07

Results

Posted Dec 21, 2022

Participant flow

The study included a screening period (up to 28 days), a double-blind induction treatment period (12 weeks), and a 2-week and a 4-week follow-up period. The target population consisted of male or female participants aged between 16 and 80 years (inclusive), with moderately to severely active ulcerative colitis (UC).

Participant flow — Overall Study
MilestoneEtrasimod 2 mgPlacebo
Started238116
Completed213103
Not completed2513
Withdrew: Protocol deviation11
Withdrew: Physician decision42
Withdrew: Participant decision01
Withdrew: Lack of efficacy40
Withdrew: Adverse event90
Withdrew: Withdrawal by subject68
Withdrew: Didn't meet inclusion/exclusion criteria10
Withdrew: Lost to follow-up01

Outcome measures

PrimaryPercentage of Participants Achieving Clinical Remission

Clinical remission was based on the modified Mayo score (MMS). The MMS is a composite score of 3 assessments consisting of participant-reported symptoms using daily electronic (e)-diary and centrally read endoscopy: stool frequency (SF), rectal bleeding (RB) and endoscopic score (ES). Clinical remission was defined as SF sub-score = 0 (or = 1 with a greater than or equal to \[\>=\] 1-point decrease from Baseline), RB sub-score = 0, and ES less than or equal to (\<=) 1 (excluding friability). Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Remission
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Clinical Remission24.815.2
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.026 · Risk difference (rd): 9.69 · 95% CI 1.14 to 18.23
SecondaryPercentage of Participants Achieving Endoscopic Improvement

Endoscopic improvement was defined as an ES \<= 1 (excluding friability). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease); higher score indicated more severe disease.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Endoscopic Improvement
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Endoscopic Improvement30.618.8
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.009 · Risk difference (rd): 12.11 · 95% CI 3.00 to 21.23
SecondaryPercentage of Participants Achieving Symptomatic Remission

Symptomatic remission was defined as an SF sub-score = 0 (or = 1 with a \>= 1 point decrease from Baseline) and RB sub-score = 0. The SF sub-score ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicated more severe disease.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Symptomatic Remission
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Symptomatic Remission46.829.5
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.001 · Risk difference (rd): 17.48 · 95% CI 6.81 to 28.15
SecondaryPercentage of Participants With Mucosal Healing

Mucosal healing was defined as an ES \<= 1 (excluding friability) with histologic remission measured by a Geboes Index score less than \[\<\] 2.0). The ES ranged from 0 to 3 (where 0 = normal/inactive disease and 3 = severe disease). The Geboes score grading system, was a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicated more severe disease.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Mucosal Healing
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants With Mucosal Healing16.28.9
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.036 · Risk difference (rd): 7.44 · 95% CI 0.50 to 14.39
SecondaryPercentage of Participants Achieving Clinical Response

Clinical response was based on the MMS which is a composite score of 3 assessments: SF, RB and ES. Clinical response was defined as a \>= 2-point and \>= 30 percent (%) decrease from Baseline MMS, and a \>= 1-point decrease from Baseline in RB sub-score or an absolute RB sub-score \<= 1. Each component sub-score ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Clinical Response
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Clinical Response62.241.1
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 21.23 · 95% CI 10.18 to 32.29
SecondaryPercentage of Participants Achieving Endoscopic Normalization

Endoscopic normalization was defined as an ES = 0. The ES ranged from 0 to 3 (where 0= normal/inactive disease and 3= severe disease); higher score indicated more severe disease.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Endoscopic Normalization
Percentage of participantsEtrasimod 2 mgPlacebo
Percentage of Participants Achieving Endoscopic Normalization17.18.0
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.009 · Risk difference (rd): 9.24 · 95% CI 2.27 to 16.20
SecondaryPercentage of Participants Achieving Symptomatic Remission at Weeks 2, 4 and 8

Symptomatic remission was defined as an SF sub-score = 0 (or = 1 with a \>= 1 point decrease from Baseline) and RB sub-score = 0. The SF sub-score ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicated more severe disease.

Time frame:
Weeks 2, 4 and 8
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Symptomatic Remission at Weeks 2, 4 and 8
Percentage of participantsEtrasimod 2 mgPlacebo
Week 216.210.7
Week 427.516.1
Week 838.724.1
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.115 · Risk difference (rd): 5.85 · 95% CI -1.42 to 13.13
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.007 · Risk difference (rd): 11.83 · 95% CI 3.19 to 20.47
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.003 · Risk difference (rd): 14.84 · 95% CI 4.98 to 24.69
SecondaryPercentage of Participants Achieving Complete Symptomatic Remission

Complete symptomatic remission was defined as an SF sub-score = 0 and RB sub-score = 0. The SF sub-score ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). Higher scores indicated more severe disease.

Time frame:
Weeks 2, 4, 8 and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Complete Symptomatic Remission
Percentage of participantsEtrasimod 2 mgPlacebo
Week 24.51.8
Week 411.73.6
Week 814.07.1
Week 1218.08.9
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.128 · Risk difference (rd): 2.83 · 95% CI -0.81 to 6.48
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.002 · Risk difference (rd): 8.32 · 95% CI 3.01 to 13.64
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.032 · Risk difference (rd): 7.06 · 95% CI 0.62 to 13.49
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.014 · Risk difference (rd): 9.18 · 95% CI 1.82 to 16.54
SecondaryPercentage of Participants Achieving Non-invasive Clinical Response

Non-invasive clinical response was defined as a \>= 30% decrease from Baseline in composite RB and SF sub-scores, and a \>= 1 point decrease from Baseline in RB sub-score or RB sub-score \<= 1. The SF subscore ranged from 0 to 3 (where 0 = normal number of stools and 3 = at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0 = no blood and 3 = blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.

Time frame:
Weeks 2, 4, 8 and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Non-invasive Clinical Response
Percentage of participantsEtrasimod 2 mgPlacebo
Week 239.224.1
Week 455.941.1
Week 868.045.5
Week 1267.650.0
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.002 · Risk difference (rd): 15.55 · 95% CI 5.65 to 25.46
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.007 · Risk difference (rd): 14.98 · 95% CI 4.05 to 25.91
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 22.60 · 95% CI 11.95 to 33.25
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.002 · Risk difference (rd): 17.58 · 95% CI 6.70 to 28.47
SecondaryPercentage of Participants Achieving Symptomatic Response

Symptomatic response was defined as a \>= 30% decrease from Baseline in composite RB and SF score. The SF sub-score ranged from 0 to 3 (where 0= normal number of stools and 3= at least 5 stools more than normal) and RB sub-score ranged from 0 to 3 (where 0= no blood and 3= blood alone passes). The composite RB and SF score range was from 0 to 6, with higher scores indicating more severe disease.

Time frame:
Weeks 2, 4, 8 and 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Symptomatic Response
Percentage of participantsEtrasimod 2 mgPlacebo
Week 239.624.1
Week 456.341.1
Week 868.546.4
Week 1268.550.0
Statistical analysis
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.002 · Risk difference (rd): 15.99 · 95% CI 6.07 to 25.91
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = =0.006 · Risk difference (rd): 15.45 · 95% CI 4.54 to 26.36
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 22.14 · 95% CI 11.43 to 32.85
  • Etrasimod 2 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 18.49 · 95% CI 7.65 to 29.33

Adverse events

Collected over All-cause mortality, non-serious Treatment-emergent adverse events (TEAEs) and Serious adverse events (SAEs) were collected from first dose of study intervention (Day 1) up to 30 days following discontinuation of the study intervention.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Etrasimod 2 mg0/238 (0%)6/238 (2.5%)112/238 (47.1%)
Placebo0/116 (0%)2/116 (1.7%)54/116 (46.6%)
Most frequent serious events
Most frequent serious events
EventEtrasimod 2 mgPlacebo
Colitis ulcerativeGastrointestinal disorders3/2380/116
Abdominal pain upperGastrointestinal disorders0/2381/116
AnaemiaBlood and lymphatic system disorders0/2381/116
Coronary artery diseaseCardiac disorders1/2380/116
Hepatobiliary procedural complicationInjury, poisoning and procedural complications1/2380/116
MigraineNervous system disorders1/2380/116
Most frequent other events
Showing 10 of 191
Most frequent other events
EventEtrasimod 2 mgPlacebo
AnaemiaBlood and lymphatic system disorders14/2388/116
HeadacheNervous system disorders11/2382/116
NauseaGastrointestinal disorders10/2382/116
MigraineNervous system disorders1/2384/116
Colitis ulcerativeGastrointestinal disorders8/2381/116
PyrexiaGeneral disorders8/2383/116
Abdominal painGastrointestinal disorders3/2383/116
COVID-19Infections and infestations3/2383/116
Iron deficiency anaemiaBlood and lymphatic system disorders3/2383/116
ArthralgiaMusculoskeletal and connective tissue disorders4/2383/116

Baseline characteristics

Full Analysis Set: All randomized participants who received at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(Years)Etrasimod 2 mgPlaceboTotal
Mean40.3 ± 13.4940.4 ± 13.2840.4 ± 13.40
Sex: Female, Male
Sex: Female, Male(Participants)Etrasimod 2 mgPlaceboTotal
Female10343146
Male13573208
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Etrasimod 2 mgPlaceboTotal
Hispanic or Latino10919
Not Hispanic or Latino226107333
Unknown or Not Reported202
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Etrasimod 2 mgPlaceboTotal
American Indian or Alaska Native617
Asian472572
Native Hawaiian or Other Pacific Islander000
Black or African American224
White17688264
More than one race101
Unknown or Not Reported606
08

Study locations

407 sites
  • Digestive Health Specialists of the Southeast
    Dothan, Alabama 36305, United States
  • East View Medical Research, LLC
    Mobile, Alabama 36606, United States
  • Arizona Digestive Health
    Sun City, Arizona 85351, United States
  • Om Research, LLC
    Lancaster, California 93534, United States
  • Entertainment Medical Group, Inc.
    Los Angeles, California 90036, United States
  • United Medical Doctors
    Murrieta, California 92563, United States
  • ACRC Studies,LLC
    San Diego, California 92119, United States
  • Paradigm Clinical Research Institute
    Torrance, California 90505, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80920, United States
  • Gastro Florida
    Clearwater, Florida 33761, United States
  • Gastro Florida
    Clearwater, Florida 33762, United States
  • Florida Center for Gastroenterology
    Largo, Florida 33777, United States
  • Life Medical Center & Research, Inc
    Miami Lakes, Florida 33014, United States
  • Global Life Research Network, LLC
    Miami, Florida 33155, United States
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • NSB Research
    New Smyrna Beach, Florida 32168, United States
  • Pediatric & Adult Research Center
    Orlando, Florida 32825, United States
  • IMIC, Inc.
    Palmetto Bay, Florida 33157, United States
  • Advanced Medical Research Center
    Port Orange, Florida 32127, United States
  • Theia Clinical Research, LLC
    Saint Petersburg, Florida 33709, United States
  • Lenus Research & Medical Group, LLC
    Sweetwater, Florida 33172, United States
  • USF Department of Surgery
    Tampa, Florida 33606, United States
  • GCP Clinical Research
    Tampa, Florida 33609, United States
  • Guardian Angel Research Center
    Tampa, Florida 33614, United States
  • Florida Medical Clinic, P.A.
    Zephyrhills, Florida 33542, United States
  • Atlanta Gastroenterology Associates
    Atlanta, Georgia 30342, United States
  • Children's Center for Digestive Health Care, LLC
    Atlanta, Georgia 30342, United States
  • Atlanta Center for Gastroenterology, P.C.
    Decatur, Georgia 30033, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Illinois Gastroenterology Group
    Gurnee, Illinois 60031, United States
  • Texas Digestive Disease Consultants
    Baton Rouge, Louisiana 70809, United States
  • Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Gastro Center of Maryland
    Columbia, Maryland 21045, United States
  • West Michigan Clinical Research Center
    Wyoming, Michigan 49519, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Sierra Clinical Research
    Las Vegas, Nevada 89106, United States
  • Las Vegas Medical Research
    Las Vegas, Nevada 89113, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Great Lakes Medical Research, LLC - Mentor
    Mentor, Ohio 44060, United States
  • Care Access Research
    Poland, Ohio 44514, United States
  • Great Lakes Medical Research, LLC - Harrisburg
    Harrisburg, Pennsylvania 17110, United States
  • Tri-Cities Gastroenterology
    Kingsport, Tennessee 37663, United States
  • GI for Kids
    Knoxville, Tennessee 37916, United States
  • Texas Clinical Research Institute, LLC
    Arlington, Texas 76012, United States
  • The University of Texas at Austin Dell Medical School
    Austin, Texas 78712, United States
  • Texas Gastroenterology Associates, PA
    Cypress, Texas 77429, United States
  • Texas Digestive Disease Consultants - Dallas
    Dallas, Texas 76092, United States
  • DHAT Research Institute
    Garland, Texas 75044, United States
  • Baylor Gastroenterology Assoc
    Houston, Texas 77030, United States
  • Rio Grande Gastroenterology
    McAllen, Texas 78503, United States
  • Texas Digestive Disease Consultants - San Marcos
    San Marcos, Texas 78130, United States
  • Tyler Research Institute, LLC
    Tyler, Texas 75701, United States
  • Victoria Gastroenterology
    Victoria, Texas 77904, United States
  • Care Access Research LLC
    Ogden, Utah 84403, United States
  • Blue Ridge Medical Research
    Lynchburg, Virginia 24502, United States
  • Washington Gastroenterology
    Bellevue, Washington 98004, United States
  • Virginia Mason
    Seattle, Washington 98101, United States
  • Marshall University Department of Clinical Research
    Huntington, West Virginia 25701, United States
  • Medical College of Wisconsin Clinical Trials Office
    Milwaukee, Wisconsin 53226-0509, United States
  • Clinica Adventista Belgrano
    Caba, Buenos Aires C1430EGF, Argentina
  • Mautalen Salud e Investigacion
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1128AAF, Argentina
  • Fundación Respirar- Centro Médico Dra. De Salvo
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1426ABP, Argentina
  • Instituto de Investigaciones Clínicas Quilmes SRL
    Quilmes, Buenos Aires B1878GEG, Argentina
  • CICE Sanatorio 9 de Julio
    San Miguel de Tucuman, Tucuman 4000, Argentina
  • Bankstown-Lidcombe Hospital
    Bankstown, New South Wales 2200, Australia
  • Nepean Hospital
    Kingswood, New South Wales 2747, Australia
  • Coastal Digestive Health
    Maroochydore, Queensland 4558, Australia
  • Coral Sea Clinical Research Institute
    North Mackay, Queensland 4740, Australia
  • Footscray Hospital
    Footscray, Victoria 3011, Australia
  • Austin Health
    Heidelberg, Victoria 3084, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Liverpool Hospital
    Liverpool, 2170, Australia
  • Alfred Hospital
    Melbourne, 3004, Australia
  • Lkh Univ. Klinikum Graz
    Graz, 8036, Austria
  • KH der Barmherzigen Brüder Linz, Interne Abteilung
    Linz, 4020, Austria
  • AKH - Medizinische Universität Wien
    Wien, 1090, Austria
  • Institution "Gomel Regional Clinical Hospital"
    Gomel, 246029, Belarus
  • Grodno City Clinical Hospital #4
    Grodno, 230026, Belarus
  • Vitebsk Regional Clinical Hospital
    Vitebsk, 210037, Belarus
  • Vitebsk Regional Clinical Specialized Center
    Vitebsk, 210604, Belarus
  • University Hospital Antwerp Gastroenterology and Hepatology Department
    Edegem, Antwerp 2650, Belgium
  • Dr. Peter Bossuyt - GI Clinical Research Center
    Bonheiden, 2820, Belgium
  • AZ Sint-Lucas & Volkskliniek
    Gent, 9000, Belgium
  • UZ Gent - Gastroenterology
    Gent, 9000, Belgium
  • UZ Leuven Campus Gasthuisberg
    Leuven, 3000, Belgium
  • AZ Sint-Maarten
    Mechelen, 2800, Belgium
  • ZNA Jan Palfijn
    Merksem, 2170, Belgium
  • AZ Delta
    Roeselare, 8800, Belgium
  • UMHAT "Sv. Georgi", EAD
    Plovdiv, 4002, Bulgaria
  • UMHAT Kanev AD, Ruse
    Ruse, 7002, Bulgaria
  • Diagnostic-Consultative Center I - Sliven, EOOD
    Sliven, 8800, Bulgaria
  • ACIBADEM CITY CLINIC TOKUDA HOSPITAL EAD,Clinical Research Center
    Sofia, 1407, Bulgaria
  • DCC "Alexandrovska", EOOD
    Sofia, 1431, Bulgaria
  • UMHAT "Tsaritsa Yoanna-ISUL" EAD
    Sofia, 1527, Bulgaria
  • UMHATEM "N.I.Pirogov" EAD, Gastroenterology Department/Clinical Research center
    Sofia, 1606, Bulgaria
  • Diagnostic Consultation Center CONVEX EOOD
    Sofia, 1680, Bulgaria
  • Acibadem City Clinic University Hospital EOOD
    Sofia, 1784, Bulgaria

Showing the first 100 of 407 sites across 41 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Dec 2021, 14 months.

Results were first posted in Dec 2022, 1 year after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 14 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2019
First posted
Jun 24, 2019
StartActual
Sep 15, 2020
Primary completionActual
Dec 7, 2021
CompletionActual
Dec 7, 2021
Results first posted
Dec 21, 2022
Last update
Dec 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03996369
Responsible party
Sponsor
First posted
Jun 24, 2019
Start date
Sep 15, 2020
Primary completion
Dec 7, 2021
Completion
Dec 7, 2021
Results posted
Dec 21, 2022
Last update
Dec 21, 2022

Study contacts

Arena CT.gov Administrator
study director · Arena Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etrasimod

Start the discussion